

GLAXOSMITHKLINE PLC  
Form 3  
April 16, 2019

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â GLAXOSMITHKLINE PLC		(Month/Day/Year)	Turning Point Therapeutics, Inc. [TPTX]	
(Last)	(First)	(Middle)	04/16/2019	
980 GREAT WEST ROAD			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
BRENTFORD			<input checked="" type="checkbox"/> Director	<input checked="" type="checkbox"/> 10% Owner
MIDDLESEX,Â X0Â TW8 9GS			<input type="checkbox"/> Officer	<input type="checkbox"/> Other
(City)	(State)	(Zip)	(give title below)	(specify below)
				6. Individual or Joint/Group Filing(Check Applicable Line)
				<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 3

Series C Preferred Stock	Â (1)	Â (1)	Common Stock	1,120,730 (2)	\$ (1)	I	See Footnote (4)
Series D Preferred Stock	Â (3)	Â (3)	Common Stock	546,820 (2)	\$ (3)	I	See Footnote (4)

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GLAXOSMITHKLINE PLC 980 GREAT WEST ROAD BRETFORD MIDDLESEX, X0 TW8 9GS	Â X	Â X	Â	Â

## Signatures

/s/ Victoria A. Whyte, SVP & Company Secretary,  
GlaxoSmithKline plc

04/16/2019

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares of Series C Preferred Stock are convertible at any time at the election of the holder without payment of further consideration.

(1) Each share of Series C Preferred Stock will automatically convert into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.

(2) Share numbers give effect to the reverse split of each share of the Issuer's Common Stock into 0.25974026 shares of Common Stock, effected on April 5, 2019, which will be effective for the Preferred Stock upon its conversion to Common Stock upon the closing of the Issuer's initial public offering.

The shares of Series D Preferred Stock are convertible at any time at the election of the holder without payment of further consideration.

(3) Each share of Series D Preferred Stock will automatically convert into 0.25974026 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.

(4) The shares reported herein are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.